Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2198 in Hemodialysis CKD-Associated Moderate-to-Severe Pruritus (Phase III)
CTR20241840Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of difelikefalin in chronic kidney disease (CKD), sponsored by Qilu Pharmaceutical. Started May 2024; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20241840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241840.